| miR Sentinel prostate cancer test |
|
A liquid biopsy urine test that can detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific captures and lyses exosomes from the patient’s urine sample, then interrogates the extracted sncRNA in a high-throughput OpenArray system. A proprietary algorithm calculates patient results and provides cancer detection and classification with one of four molecular assessments of the prostate gland: no molecular evidence of prostate cancer, low risk, moderate risk, or elevated risk for aggressive prostate cancer. In October 2020, this test was granted FDA BDD. In 2022, it was CLIA-approved as an LTD. miR Scientific is working to bring miR Sentinel to all 50 U.S. states, all territories, and global markets, including Canada, Israel, and Singapore. |
